Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trial.,Diabetes, Obesity and Metabolism

当前位置： X-MOL 学术 › Diabetes Obes. Metab. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trial.
Diabetes, Obesity and Metabolism ( IF 5.8 ) Pub Date : 2020-03-29 , DOI: 10.1111/dom.14015
Subodh Verma ₁ , Abhinav Sharma ₂ , Bernard Zinman ₃ , Anne Pernille Ofstad ₄ , David Fitchett ₅ , Martina Brueckmann _{6,

7} , Christoph Wanner ₈ , Isabella Zwiener ₉ , Jyothis T George ₆ , Silvio E Inzucchi ₁₀ , Javed Butler ₁₁ , C David Mazer ₁₂

Affiliation

Division of Cardiac Surgery, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
McGill University Health Centre, McGill University, Montreal, Quebec, Canada.
Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.
Boehringer Ingelheim Norway KS, Asker, Norway.
Division of Cardiology, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
Boehringer Ingelheim International GmbH, Ingelheim, Germany.
Faculty of Medicine Mannheim of the University of Heidelberg, Mannheim, Germany.
Würzburg University Clinic, Würzburg, Germany.
Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.
Yale University School of Medicine, New Haven, Connecticut.
Department of Medicine, University of Mississippi Medical Center, Jackson, Mississippi.
Department of Anesthesia, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.

To investigate the association of the Thrombolysis In Myocardial Infarction (TIMI) Risk Score for Heart Failure in Diabetes (TRS‐HF_DM) with mortality using data from the EMPA‐REG OUTCOME trial.

中文翻译：

Empagliflozin 可降低糖尿病心力衰竭心肌梗塞风险评分中溶栓治疗期间心力衰竭的死亡率和住院风险：EMPA-REG OUTCOME 试验的事后分析。

使用 EMPA-REG OUTCOME 试验的数据研究心肌梗死溶栓 (TIMI) 糖尿病心力衰竭风险评分 (TRS-HF _{DM ) 与死亡率之间的关系。}

更新日期：2020-03-29

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文

全部期刊列表>>